touchDERMATOLOGY touchDERMATOLOGY
Psoriasis
Watch Time: 3 mins

POETYK PSO LTE study findings of deucravacitinib in plaque psoriasis: Leon Kircik, EADV 2023

Copy Link
Published Online: Oct 17th 2023

The POETYK PSO long term extension (LTE) study investigated the efficacy and safety of deucravacitinib at 3 years in patients with plaque psoriasis (NCT04036435).

touchDERMATOLOGY were delighted to speak with Dr. Leon. Kircik around the mechanism of action of deucravacitinib, the clinical data supporting its use in clinical practice, and the long term efficacy and safety data from the POETYK PSO LTE.

This information is provided solely by Touch Medical Media and is independent of any sponsorship or affiliation with the European Academy of Dermatology & Venereology (EADV).

Questions

  1. What is the mechanism of action of deucravacitinib? (0:21)
  2. What clinical evidence already supports the use of deucravacitinib? (0:41)
  3. What were the findings from the POETYK PSO long-term extension trial? (1:25)
  4. How will these insights optimise the use of deucravacitinib in plaque psoriasis? (2:10)
  5. In which patients is deucravacitinib most beneficial? (2:43)

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch.

Filmed in coverage of the EADV Annual Meeting.

Click here for more content on psoriasis & for further EADV 2023 highlights visit here.

Disclosures:

Leon Kircik has the following disclosure information:

H = Honorarium; G = Grant

  • Abbott Laboratories: Speaker (H)
  • Abbvie: Consultant (H), Investigator (G)
  • Ablynx: Investigator (G)
  • Aclaris: Advisory Board (H)
  • Acambis: Investigator (G)
  • Allergan, Inc.: Investigator (H), Advisory Board (H), Speaker (H), Consultant (H)
  • Almirall: Consultant (H), Investigator (G), Speaker (H), Advisory Board (H)
  • Amgen, Inc.: Consultant (H), Investigator (G), Speaker (H), Advisory Board (H)
  • Anacor Pharmaceuticals: Investigator (G), Consultant (H), Advisory Board (H)
  • Anaptys: Investigator (G)
  • Arcutis: Investigator (G), Advisory Board (H), Consultant (H)
  • Arena: Investigator (G), Advisory Board (H)
  • Assos Pharma: Speaker (H)
  • Astellas Pharma US, Inc.: Investigator (G), Speaker (H)
  • Asubio: Investigator (G)
  • Bausch Health: Investigator (G)
  • Berlex Laboratories (Bayer HealthCare Pharmaceuticals): Investigator (G)
  • Biogen-Idec: Advisory Board (H)
  • Biolife: Investigator (G)
  • Biomimterix: Investigator (G)
  • Biopelle: Investigator (G)
  • BMS: Consultant (H), Investigator (G), Advisory Board (H)
  • Boehringer-Ingleheim: Investigator (G)
  • Breckinridge Pharma: Investigator (G)
  • Cassiopea: Consultant (H), Advisory Board (H)
  • Centocor, Inc.: Investigator (G)
  • Cellceutix: Investigator (G)
  • Cipher: Consultant (H), Speaker (H), Advisory Board (H)
  • Coherus: Investigator (G)
  • Colbar: Consultant (H), Advisory Board (H)
  • Combinatrix: Investigator (G)
  • Connetics Corporation: Advisory Board (H), Consultant (H), Speaker (H), Investigator (G)
  • Coria: Investigator (G)
  • Dermavant: Investigator (G), Consultant (H), Speaker (H), Advisory Board (H)
  • Dermira: Investigator (G), Consultant (H), Speaker (H), Advisory Board (H)
  • Dermik Laboratories: Speaker (H)
  • Dow Pharmaceutical Sciences, Inc.: Investigator (G)
  • Dr. Reddy’s Lab: Investigator (G), Consultant (H), Advisory Board (H)
  • Dusa: Investigator (G)
  • Embil Pharmaceuticals: Speaker (H)
  • Eli Lilly: Investigator (G), Speaker (H), Advisory Board (H), Consultant (H)
  • EOS: Advisory Board (H)
  • Exeltis: Advisory Board (H), Consultant (H), Speaker (H), Investigator (G)
  • Ferndale Laboratories, Inc.: Advisory Board (H), Investigator (G)
  • Foamix: Investigator (G), Advisory Board (H)
  • Ferrer: Consultant (H), Speaker (H)
  • Galderma: Consultant (H), Speaker (H), Advisory Board (H), Investigator (G)
  • Genentech, Inc.: Advisory Board (H), Speaker (H), Investigator (G), Consultant (H)
  • GlaxoSmithKline, PLC: Investigator (G), Speaker (H), Consultant (H), Advisory Board (H)
  • Glenmark: Investigator (G), Advisory Board (H)
  • Health Point, LTD: Investigator (G)
  • Idera: Investigator (G)
  • Incyte: Investigator (G), Advisory Board (H)
  • Intendis: Advisory Board (H), Consultant (H), Investigator (G)
  • Innocutis: Speaker (H), Advisory Board (H)
  • Innovail: Speaker (H)
  • Isdin: Advisory Board (H), Consultant (H)
  • Johnson & Johnson: Consultant (H), Investigator (G), Advisory Board (H), Speaker (H)
  • Kyowakirin: Speaker (H)
  • Laboratory Skin Care Inc.: Consultant (H)
  • Leo: Investigator (G), Consultant (H), Speaker (H)
  • L’Oreal: Investigator (G), Speaker (H)
  • 3M: Speaker (H), Investigator (G)
  • Maruho: Investigator (G)
  • Medical International Technologies: Consultant (H)
  • Merck: Consultant (H), Investigator (G)
  • Medicis Pharmaceutical Corp.: Investigator (G)
  • Merz: Consultant (H)
  • Nano Bio: Advisory Board (H), Investigator (G)
  • Nektar: Investigator (G)
  • Nimbus: Investigator (G)
  • Novartis AG: Investigator (G), Consultant (H), Speaker (H), Advisory Board (H)
  • Noven Pharmaceuticals: Investigator (G)
  • Nucryst Pharmaceuticals Corp: Investigator (G)
  • Obagi: Investigator (G)
  • Onset: Investigator (G), Speaker (H)
  • OrthoNeutrogena: Speaker (H), Investigator (G), Advisory Board (H), Consultant (H)
  • PediaPharma: Speaker (H)
  • Pfizer: Investigator (G)
  • Promius: Investigator (G), Consultant (H), Advisory Board (H)
  • PuraCap: Consultant (H)
  • PharmaDerm: Investigator (G), Speaker (H)
  • QLT, Inc: Investigator (G)
  • Quinnova: Investigator (G), Advisory Board (H)
  • Quatrix: Investigator (G)
  • Rapt: Investigator (G), Consultant (H)
  • Regeneron: Investigator (G), Speaker (H)
  • Sanofi: Speaker (H), Investigator (G), Consultant (H), Advisory Board (H)
  • Serono (Merck Serono International SA): Speaker (H)
  • SkinMedica, Inc.: Consultant (H), Investigator (G), Advisory Board (H), Speaker (H)
  • Stiefel Laboratories, Inc.: Speaker (H), Investigator (G), Advisory Board (H), Consultant (H)
  • Sun Pharma: Consultant (H), Advisory Board (H), Speaker (H), Investigator (G)
  • Taro: Consultant/Speaker (H)
  • TolerRx: Investigator (G)
  • Triax: Speaker (H)
  • UCB: Investigator (G), Consultant (H), Speaker (H)
  • Valeant Pharmaceuticals Intl: Advisory Board (H), Investigator (G), Consultant (H), Speaker (H)
  • Ventyx: Investigator
  • Warner-Chilcott: Advisory Board (H), Speaker (H), Investigator (G)
  • XenoPort: Investigator (G)
  • ZAGE: Consultant (H)
Share this Video
Related Videos In Psoriasis
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72